caa a22 4500 605520372 CHVBK 20210128100735.0 cr unu---uuuuu 210128e20150701xx s 000 0 eng 10.1007/s00223-015-0006-5 doi (NATIONALLICENCE)springer-10.1007/s00223-015-0006-5 Effect of Combined Teriparatide and Monthly Risedronate Therapy on Cancellous Bone Mass in Orchidectomized Rats: A Bone Histomorphometry Study [Elektronische Daten] [Jun Iwamoto, Azusa Seki] This study investigated the effects of combined teriparatide (an anabolic agent) and monthly risedronate (an anti-resorptive agent) therapy on cancellous bone mass in orchidectomized (ORX) rats. Fifty 14-week-old male Sprague-Dawley rats were randomized into five groups of ten animals each: sham-operation+vehicle; ORX+vehicle; ORX+risedronate (90μg/kgsubcutaneous, every 4weeks); ORX+teriparatide (30μg/kgsubcutaneous, three times per week); and ORX+risedronate+teriparatide. After the 12-week experimental period, cancellous bone in the tibial proximal metaphysis was examined by static and dynamic histomorphometric analyses. ORX decreased bone volume per total volume (BV/TV) and trabecular number (Tb.N), and increased trabecular separation (Tb.Sp). Risedronate increased BV/TV and Tb.N above the sham control values, while teriparatide prevented the ORX-induced decrease in BV/TV and increased trabecular width (Tb.Wi) above sham control levels. Risedronate decreased Tb.Sp below control values, while teriparatide prevented the ORX-induced increase in Tb.Sp. The combination of teriparatide and risedronate further increased BV/TV and Tb.N and decreased Tb.Sp as a result of suppression of bone remodeling, compared with teriparatide alone. These results suggest that teriparatide and monthly risedronate exert different effects on cancellous bone structure and thus have additive effects on cancellous bone mass in ORX rats. Springer Science+Business Media New York, 2015 Teriparatide nationallicence Risedronate nationallicence Cancellous bone nationallicence Bone histomorphometry nationallicence Orchidectomized rats nationallicence Iwamoto Jun Institute for Integrated Sports Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan aut Seki Azusa Hamri Co., Ltd., Koga, Ibaraki, Japan aut Calcified Tissue International Springer US; http://www.springer-ny.com 97/1(2015-07-01), 23-31 0171-967X 97:1<23 2015 97 223 https://doi.org/10.1007/s00223-015-0006-5 text/html Onlinezugriff via DOI BK010053 XK010053 XK010000 Metadata rights reserved Springer special CC-BY-NC licence nationallicence 1 research-article jats NATIONALLICENCE NATIONALLICENCE NL-springer NATIONALLICENCE 856 40 https://doi.org/10.1007/s00223-015-0006-5 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Iwamoto Jun Institute for Integrated Sports Medicine, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, 160-8582, Tokyo, Japan aut NATIONALLICENCE 700 1- Seki Azusa Hamri Co., Ltd., Koga, Ibaraki, Japan aut NATIONALLICENCE 773 0- Calcified Tissue International Springer US; http://www.springer-ny.com 97/1(2015-07-01), 23-31 0171-967X 97:1<23 2015 97 223